Health regulator’s classification has set back growth, say industry insiders. But the president says urgent work was being finalised by government to create an enabling environment
12 February 2023 – 07:20
The health regulator has been slammed for hindering growth in the cannabis industry after it classified a cannabis oil compound as a prescription medicine, and some in the sector say slow regulatory reform is also holding back progress.
“We’ve moved backwards because now they are saying even the non-psychoactive cannabinoids are schedule 6, which makes zero sense and is outside what’s happening globally,” said Gabriel Theron, CEO and founder of Cilo Cybin said…
Recent Comments